- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07649265
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
A Phase 1 Open-Label, Multicenter Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HBM7020 in Healthy Adult Participants and Adults With Seropositive Autoimmune Disease
This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020. The study will enroll healthy participants at low doses, followed by participants with moderate to severe autoimmune diseases with predominant B-cell involvement. Eligible participants include patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's disease (SjD), and rheumatoid arthritis (RA).
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Otsuka Call Center
- Telefonnummer: 844-687-3522
- E-post: otsukaprofessionalservices@otsuka-us.com
Studieorter
-
-
Queensland
-
Brisbane, Queensland, Australien, 4006
- Rekrytering
- Q-Pharm Pty Ltd
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Huvudutredare:
- Wong
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria for Healthy Participants (Part 1)
- Participants who are of non-childbearing potential or are using acceptable contraception.
- Body mass index (BMI) and body weight within an acceptable range.
- Good general health based on medical history, physical examination, electrocardiogram (ECG), and laboratory assessments.
Key Disease-Agnostic Inclusion Criteria for Patient Participants (Part 2)
- BMI and body weight within an acceptable range.
- Adequate hematologic, renal, hepatic, immunologic, and lymphocyte parameters.
Key Disease-Specific Inclusion Criteria for Patient Participants (Part 2)
-
Confirmed autoimmune disease with appropriate supporting autoantibody findings.
-
Stable background therapy prior to dosing.
-
Active moderate to severe disease consistent with protocol-defined disease activity criteria for:
- Systemic lupus erythematosus (SLE)
- Systemic sclerosis (SSc)
- Rheumatoid arthritis (RA)
- Sjögren's disease (SjD)
Key Inclusion Criteria for Rescreening Participants (Part 2)
- Meets Part 2 disease-agnostic inclusion criteria.
- Stable background autoimmune therapy prior to dosing.
- Ongoing active moderate to severe disease based on protocol-defined disease-specific criteria.
Key Exclusion Criteria for Parts 1 and 2
- Pregnant or breastfeeding participants.
- Recent vaccination within protocol-defined timelines.
- Clinically significant medical history or abnormal physical examination findings.
- Clinically significant cardiovascular abnormalities, including blood pressure, heart rate, syncope, or ECG findings.
- Prior or recent therapies or conditions that may interfere with study participation or safety evaluations.
- Severe pulmonary, renal, or cardiac disease, or clinically significant pulmonary hypertension.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part 1 and Part 2a Dose Escalation
Healthy participants and participants with seropositive systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), or Sjögren's disease (SjD) will receive HBM7020 in sequential dose-escalation cohorts during Part 1 and Part 2a, respectively. |
Liquid formulation, administered through intravenous infusion |
|
Experimentell: Part 2b
Eligible patients may receive optional retreatment of HBM7020 in Part 2b |
Liquid formulation, administered through intravenous infusion |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Discontinuations Due to Adverse Events Through Week 48
Tidsram: Up to Week 48
|
Up to Week 48
|
|
Number of Participants With Signs Characteristic of Cytokine Release Syndrome (CRS), Immune Related Reaction (IRR), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Including Immunosuppression-Related Infection
Tidsram: Up to Week 24
|
Up to Week 24
|
|
Number of Participants With Dose limiting AE Evaluation During Dose Escalation
Tidsram: Up to Day 15
|
Up to Day 15
|
|
Number of Participants With Clinically Significant Changes in Vital Signs
Tidsram: Up to Week 24
|
Up to Week 24
|
|
Number of Participants With Clinically Significant Changes in Physical Examination Findings
Tidsram: Up to Week 24
|
Up to Week 24
|
|
Change From Baseline in Serum High Sensitivity C-Reactive Protein (hsCRP)
Tidsram: Up to Week 20
|
Up to Week 20
|
|
Change From Baseline in Serum Erythrocyte Sedimentation Rate (ESR)
Tidsram: Up to Week 20
|
Up to Week 20
|
|
Change From Baseline in Serum Ferritin
Tidsram: Up to Week 20
|
Up to Week 20
|
|
Change From Baseline in Serum Immunoglobulin G (IgG)
Tidsram: Up to Week 20
|
Up to Week 20
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Area Under the Concentration-Time Curve From Time Zero to Last Observable Concentration (AUCt) of HBM7020
Tidsram: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC∞) of HBM7020
Tidsram: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Maximum Observed Plasma Concentration (Cmax) of HBM7020
Tidsram: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Time to Maximum Observed Plasma Concentration (tmax) of HBM7020
Tidsram: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Number of Participants With Anti-Drug Antibodies (ADA) to HBM7020
Tidsram: Up to Week 24
|
Up to Week 24
|
Samarbetspartners och utredare
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Muskuloskeletala sjukdomar
- Munsjukdomar
- Stomatogena sjukdomar
- Artrit
- Ledsjukdomar
- Reumatiska sjukdomar
- Bindvävssjukdomar
- Immunsystemets sjukdomar
- Ögonsjukdomar
- Hudsjukdomar
- Xerostomi
- Spottkörtelsjukdomar
- Torra ögon syndrom
- Sjukdomar i tårapparat
- Hud- och bindvävssjukdomar
- Lupus erythematosus, systemisk
- Sjögrens syndrom
- Autoimmuna sjukdomar
- Sklerodermi, systemisk
- Artrit, reumatoid
Andra studie-ID-nummer
- 365-201-00001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Tidsram för IPD-delning
Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Kriterier för IPD Sharing Access
Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .